Mouse CD86 enzyme-linked immunoassay kit
Specification | 96 Test |
---|---|
Sensitivity | 0.28 pg/ml (10 μl) |
Standard Curve Range | 6.86~5000 pg/ml |
Standard Curve Gradient | 7 Points/3 Folds |
Number of Incubations | 2 |
Detectable sample | Liquid phase sample of soluble substances. For example: serum, plasma, cell culture supernatant, tissue grinding liquid, etc. |
Sample Volume | 10 μl |
Type | Fully Ready-to-Use |
Operation Duration | 120min |

pg/ml | O.D. | Average | Corrected | |
---|---|---|---|---|
0.00 | 0.0093 | 0.0087 | 0.0090 | |
6.86 | 0.0362 | 0.0331 | 0.0347 | 0.0257 |
20.58 | 0.0949 | 0.0995 | 0.0972 | 0.0882 |
61.73 | 0.2952 | 0.3140 | 0.3046 | 0.2956 |
185.19 | 0.7960 | 0.7331 | 0.7646 | 0.7556 |
555.56 | 1.9620 | 2.0140 | 1.9880 | 1.9790 |
1666.67 | 3.2560 | 3.1950 | 3.2255 | 3.2165 |
5000.00 | 3.8920 | 3.9040 | 3.8980 | 3.8890 |
Precision
Intra-assay Precision | Inter-assay Precision | |||||
Sample Number | S1 | S2 | S3 | S1 | S2 | S3 |
22 | 22 | 22 | 6 | 6 | 6 | |
Average(pg/ml) | 182.88 | 551.76 | 1826.16 | 159.79 | 469.11 | 1545.97 |
Standard Deviation | 7.55 | 19.78 | 110.28 | 8.75 | 26.99 | 89.35 |
Coefficient of Variation(%) | 4.1 | 3.6 | 6.0 | 5.5 | 5.8 | 5.8 |
Intra-assay Precision (Precision within an assay) Three samples of known concentration were tested twenty times on one plate to assess intra-assay precision.
Inter-assay Precision (Precision between assays) Three samples of known concentration were tested six times on one plate to assess intra-assay precision.
Spike Recovery
The spike recovery was evaluated by spiking 3 levels of mouse CD86 into health mouse serum sample. The un-spiked serum was used as blank in this experiment.
The recovery ranged from 97% to 104% with an overall mean recovery of 99%.
Sample Values
Sample Matrix | Sample Evaluated | Range (pg/ml) | Detectable (%) | Mean of Detectable (pg/ml) |
---|---|---|---|---|
Serum | 30 | 119.78-359.50 | 100 | 265.68 |
Serum/Plasma – Thirty samples from apparently healthy mice were evaluated for the presence of CD86 in this assay. No medical histories were available for the donors. n.d. = non-detectable. Samples measured below the sensitivity are considered to be non-detectable.
Product Data Sheet
Background: CD86
B7-2, also known as CD86, B70, and ETC-1, is a 60-100 kDa variably glycosylated protein in the B7 family. B7 family members are transmembrane cell surface molecules that play important roles in immune activation and the maintenance of immune tolerance. Mature human B7-2 consists of a 224 amino acid (aa) extracellular domain (ECD) with two Ig-like domains, a 21 aa transmembrane segment, and a 61 aa cytoplasmic tail (3, 4). Within the ECD, human B7-2 shares 59% aa sequence identity with mouse and rat B7-2. Alternative splicing of human B7-2 generates additional isoforms that lack both Ig-like domains or a region that includes the transmembrane segment. B7-2 is highly expressed on activated antigen presenting cells (APC), e.g. B cells, dendritic cells, and monocytes, as well as on vascular endothelial cells. B7-2 and the closely related B7-1/CD80 exhibit overlapping but distinct functional properties. Their binding to CD28, which is constitutively expressed on T cells, enhances T cell receptor signaling and also provides TCR-independent co-stimulation. B7-1 and B7-2 additionally bind the CD28-related protein, CTLA-4, which is up‑regulated and recruited to the immunological synapse (IS) at the onset of T cell activation. CTLA-4 ligation inhibits the T cell response and supports regulatory T cell function. B7-2 is expressed earlier than B7-1 following APC activation, and both proteins bind with higher affinity to CTLA-4 than to CD28. B7-2 promotes the stabilization of CD28 in the IS, while B7-1 is primarily responsible for promoting CTLA-4 recruitment and accumulation in the IS. The relative participation of B7-1 and B7-2 in T cell co-stimulation can also alter the Th1/Th2 bias of the immune response. Both B7-1 and B7-2 serve as cellular receptors for B species adenoviruses.